Who is eligible for clinical trial NCT07615270?

Participants must meet the protocol's inclusion criteria for AL Amyloidosis. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07615270 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement (NCT07615270)

A Pilot Study of CAEL-101/Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement

🟡 Not Yet Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: Stanford University

🩺 Plain-English Summary (8th-Grade Level)

This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (17 items) and avoid the listed exclusions (17 items).

Location: Stanford University — Palo Alto, California

Age range: 18 Years

🧪 Interventions in This Study

Anselamimab (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Use of other investigational agents within 30 days of screening
Taking doxycycline within 30 days of screening
Current significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders, or psychiatric disorder.
Major surgery within 4 weeks of enrollment
Pregnant
Breast feeding
Participant is eligible and agreeable to standard of care chemotherapy.
Presence of active infection at the time of screening
Participant with a monoclonal protein or isotypic light chain predominance (increased level of the involved light chain and abnormal free light chain ratio (\<0.26 or \>1.65)) ☐ ☐
Participant with known or suspected systemic AL amyloidosis, or suspicion of other organ involvement.
Lymph node involvement

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Stanford University — Palo Alto, California

📞 Contact the Study Coordinator

Phone: (650) 723-0501

Email: mgupta4@stanford.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗